Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Abstract Text:

Linda L Carpenter,Lily Bayat,Francisco Moreno,Mitchel A Kling,Lawrence H Price,Audrey R Tyrka,Becky Kinkead,Michael J Owens,Charles B Nemeroff,Linda L Carpenter,Lily Bayat,Francisco Moreno,Mitchel A Kling,Lawrence H Price,Audrey R Tyrka,Becky Kinkead,Michael J Owens,Charles B Nemeroff,Linda L Carpenter,Lily Bayat,Francisco Moreno,Mitchel A Kling,Lawrence H Price,Audrey R Tyrka,Becky Kinkead,Michael J Owens,Charles B Nemeroff,

Recent preclinical and clinical research has demonstrated that the neuropeptide substance P (SP) plays a role in the central nervous system (CNS) response to stress, and perhaps in the etiology of major depression and/or anxiety disorders. The nature of this role, however, is poorly understood. A limited body of evidence suggests that in medication-free depressed patients, cerebrospinal fluid (CSF) concentrations of SP may be elevated relative to healthy controls. Two studies have shown that antidepressant treatment does not significantly change CSF concentrations of SP. Using standard lumbar puncture techniques, baseline CSF samples were obtained from 19 medication-free healthy controls and 19 medicated patients with treatment-resistant depression (TRD). Mean CSF SP concentration was significantly lower in TRD patients on psychotropic medications than in the group of healthy subjects. After 10-12 weeks of treatment with adjunct vagus nerve stimulation (VNS), CSF SP concentrations were not significantly changed. Low CSF SP may reflect a biological marker of the subtype of severe and chronic depression that is resistant to standard therapies.

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Publishing Authors By Initials

LL Carpenter,L Bayat,F Moreno,MA Kling,LH Price,AR Tyrka,B Kinkead,MJ Owens,CB Nemeroff,LL Carpenter,L Bayat,F Moreno,MA Kling,LH Price,AR Tyrka,B Kinkead,MJ Owens,CB Nemeroff,LL Carpenter,L Bayat,F Moreno,MA Kling,LH Price,AR Tyrka,B Kinkead,MJ Owens,CB Nemeroff,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Psychiatry research

VOLUME: 157

Page Numbers: 123-9

Journal Abbreviation:

ISSN: 0165-1781

DAY: 31

MONTH: 10

YEAR: 2007

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7911385

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.

AFFILIATION: Mood Disorders Research Program, Butler Hospital, Brown University, Providence, RI, USA. Linda.Carpenter_MD@Brown.edu

Country: Ireland

AGENCY: United States NIMH

GRANT: MH-52899

ACRONYM: MH

MEDLINETA: Psychiatry Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.